Trial Profile
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary) ; Bevacizumab; Irinotecan; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms ROCKET
- Sponsors EpicentRx
- 21 Jan 2023 Results (n=34) comparing the safety and efficacy of the combination therapy RRx-001 + irinotecan vs. regorafenib + irinotecan in 3rd/4th line colorectal cancer , presented at the 2023 Gastrointestinal Cancers Symposium
- 20 Jan 2023 According to an EpicentRx media release, this study was carried out in collaboration with Dr. Keola Beale from Kaiser Permanente Moanalua Medical Center.
- 20 Jan 2023 According to an EpicentRx media release, data from this study will be presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.